Highlights from the 2020 CHDI HD Therapeutics Conference are now here! This year’s Postcard covers HTT-lowering therapeutics, including an
Update from Prilenia Regarding PROOF-HD Clinical Trials
Dear Huntington disease (HD) community,
We have received an update on PROOF-HD, the phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine 45 mg BID in patients with early stage HD.
We encourage you to read Prilenia’s letter to the community here: https://www.huntingtonsociety.ca/wp-content/uploads/2023/04/PROOF-HD-Community-Letter.pdf
Please stay tuned for our announcement of a webinar co-hosted with the Huntington’s Disease Society of America (HDSA) during which we will share more results and answer questions about this update and the trial.
I want to extend our heartfelt thanks to all of the clinical trials participants who make possible the learning and discovery process. We hope that information from this trial will help inform the future development of therapies.
HD Clinics: Questions specific to trial participation can be discussed with the HD clinic you attend. For information on the HD clinic near you: https://www.huntingtonsociety.ca/hd-clinics-in-canada/
HSC Family Services (FS) are available to provide support, education on HD, resources and referrals. Individuals and families can find the contact information for the nearest FS team member here: https://www.huntingtonsociety.ca/family-services-team-list/
You can also submit a general request for support or resources here: https://contactme.cloud/form/huntingtonsociety
Huntington Society of Canada